Table 1.
Baseline patient characteristics in the escalation and expansion phases.
| Escalation phase | Expansion phase | |
|---|---|---|
| (total n = 34) | (total n = 40) | |
| Age (years) | ||
| Mean (SD) | 66.0 (7.65) | 59.4 (12.84) |
| Median (range) | 67.0 (42–77) | 60.5 (20–79) |
| Gender, n (%) | ||
| Male | 30 (88.2) | 16 (40.0) |
| Female | 4 (11.8) | 24 (60.0) |
| Race, n (%) | ||
| Caucasian | 26 (76.5) | 32 (80.0) |
| Black or African-American | 1 (2.9) | 2 (5.0) |
| Other | 2 (5.9) | 6 (15.0) |
| Not collected | 5 (14.7) | |
| Baseline ECOG, n (%) | ||
| Score 0 | 6 (17.6) | 14 (35.0) |
| Score 1 | 28 (82.4) | 26 (65.0) |
| Score >1 | 0 | 0 |
| Primary tumour type, n (%) | ||
| Breast | 9 (22.5) | |
| Lung | 4 (11.8) | 10 (25.0) |
| Mesothelioma | 13 (38.2) | 6 (15.0) |
| Other solid tumoura | 17 (50) | 15 (37.5) |
| MYC-amp/B-cat-mutated tumours, n (%) | 13 (32.5) | |
| Number of prior regimens, n (%) | ||
| 0 | 1 (2,9) | 0 |
| 1 | 10 (29.4) | 3 (7.5) |
| 2 | 11 (32.4) | 8 (20.0) |
| >2 | 12 (35.3) | 29 (72.5) |
| Prior radiation therapy, n (%) | ||
| Yes | 17 (50.0) | 26 (65.0) |
| Palliative | 10 (29.4) | 17 (42.5) |
| Therapeutic | 6 (17.6) | 13 (32.5) |
| N/A | 3 (8.8) | 1 (2.5) |
| No | 17 (50.0) | 14 (35.0) |
SD standard deviation, ECOG Eastern Cooperative Oncology Group, N/A not evaluable.
aColorectal, renal, ovarian, pancreatic, stomach/oesophageal/GE junction, prostate, head and neck, urothelial, endometrial, metastatic (adeno-) carcinoma of unknown primary, adrenal cortical carcinoma, choroidea melanoma, metastatic neuro-endocrine carcinoma, extra-skeletal chondrosarcoma.